Table 1.
Effect of SARS-CoV-2 infection on pregnant women.
| Pregnancy semester during infection | Maternal diagnoses | Mother antibodies | Children infected | Children antibodies | Infant complications due to maternal COVID-19 | Maternal treatment previous to delivery (as described by paper) | References |
|---|---|---|---|---|---|---|---|
| N/A | RT-PCR | Mixed, 2 mothers with high IgM and 3 with high IgG | No | Yes, mixed results. Two newborns with IgM/IgG, and three with IgG. One newborn with very low levels of IgM and IgG. | Elevated IL-6 in all infants. None of the infants presented symptoms. |
N/A | (128) |
| N/A | RT-PCR | N/A | Yes | N/A | Lymphopenia, deranged liver function tests, and elevated creatine kinase level. After 36 h post-partum tested positive for SARS-CoV-2 | N/A | (119) |
| 3° | RT-PCR | N/A | No | N/A | No | Lopinavir 200 mg and Ritonavir 50 mg (each 2 × /day), methylprednisolone (40 mg 1 × /day) | (129) |
| 3° | RT-PCR | N/A | Yes, but vertical transmission could not be confirmed | N/A | No | N/A | (130) |
| 3° | RT-PCR | Yes, IgM and IgG | No | Yes, IgM and IgG | Lymphopenia, neutrophilia, elevated aspartate aminotransferase (AST), total bilirubin, Creatine kinase, lactate dehydrogenase, IL-6, IL-10 | Antiviral, antibiotic, corticosteroid, and oxygen therapies | (120) |
| 3° | RT-PCR | N/A | No | N/A | No | Antibiotics (Gentamicin, Metronidazole and Cephazolin) | (131) |
| N/A | RT-PCR | N/A | No | N/A | N/A | N/A | (132) |
| 3° | RT-PCR | N/A | No | N/A | Neutrophilia, 2 newborns with elevated AST | N/A | (133) |
| 3° | RT-PCR | N/A | No | N/A | N/A | 3 were treated with oral oseltamivir 1 treated with oral oseltamivir and nebulized inhaled interferon 6 non-treated |
(121) |
| N/A | RT-PCR | N/A | No | N/A | 2 newborns presented skin rashes after birth | N/A | (123) |
| 3° | RT-PCR | N/A | No | N/A | No | N/A | (124) |
| N/A | RT-PCR | N/A | Yes, 3 from a 33 newborn cohort | N/A | 3 newborns presented pneumonia | N/A | (122) |
| 2° | RT-PCR | N/A | No | N/A | CRP increased and developed lymphopenia on day 5 | Antibiotic and corticosteroids | (134) |
| 1° | RT-PCR | N/A | N/A | N/A | No | No COVID-19 treatment | (135) |
| N/A | RT-PCR | N/A | Yes, 1 from a 3 newborn cohort, but vertical transmission could not be confirmed | N/A | 2 tested positive for post-partum infection, 1 died, 1 developed neutrophilia, lymphopenia, and elevated lactate dehydrogenase | N/A | (136) |
| 2° | RT-PCR | N/A | No, but the placenta was positive for SARS-CoV-2 | N/A | One stillbirth | Acetaminophen | (47) |
| 2° and 3° | RT-PCR | N/A | No vertical transmission, with one newborn acquired SARS-CoV-2 post-natally | N/A | One stillbirth | Oseltamivir 75 mg (2 × /day for 5 days); hydroxychloroquine sulfate 400 mg or chloroquine sulfate 1,000 mg (single dose) Lopinavir/ritonavir 400/100 mg and ribavirin 1,200 mg (2 × /day each for 5 days) Enoxaparin 40 mg (1 × /day) or heparin 5,000 units (2 × /day) |
(137) |